Breast carcinoma with amplified HER2: A gene expression signature specific for trastuzumab resistance and poor prognosis

Modern Pathology

Volumn 23, Issue 10, 2010, Pages 1364-1378

  Khoury, Thaer ^a   Kanehira, Kazunori ^a   Wang, Dan ^a   Ademuyiwa, Foluso ^a   Mojica, Wilfrido ^a   Cheney, Richard ^a   Morrison, Carl ^a   Conroy, Jeffrey ^a   Nowak, Norma ^a   Liu, Song ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Gene signature; HER2; Prognosis; Trastuzumab resistance

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLUSTER ANALYSIS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENES, ERBB-2; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TREATMENT OUTCOME;

EID: 77957608957     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2010.125     Document Type: Article

References (39)

1. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2: 127-137.
2. Pinkas-Kramarski R, Soussan L, Waterman H, et al. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 1996;15:2452-2467. (Pubitemid 26151185)
3. Yaziji H, Goldstein LC, Barry TS, et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 2004;291:1972-1977. (Pubitemid 38544278)
4. Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 2004;5:63-69.
5. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235: 177-182.
6. Camirand A, Lu Y, Pollak M. Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors cause synergistic inhibition of growth in HER2-overexpressing breast cancer cells. Med Sci Monit 2002;8:521-526.
7. Lu Y, Zi X, Zhao Y, et al. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001;93:1852-1857.
8. Harris LN, You F, Schnitt SJ, et al. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res 2007;13:1198-1207.
9. Joensuu H, Kellokumpu-Lehtinen PL. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809-820.
10. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2- positive breast cancer. N Engl JMed 2005;353: 1659-1672.
11. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-1684.
12. Pegram MD, Konecny GE, OCallaghan C, et al. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004;96:739-749.
13. Nahta R, Esteva FJ. Herceptin. mechanisms of action and resistance. Cancer Lett 2006;232:123-138.
14. Pegram MD. Can we circumvent resistance to ErbB2- targeted agents by targeting novel pathways? Clin Breast Cancer Suppl 2008;8(Suppl 3):S121-S130.
15. Telli ML, Hunt SA, Carlson RW, et al. Trastuzumabrelated cardiotoxicity: callin into question the concept of reversibility. J Clin Oncol 2007;25:3525-3533.
16. Tan-Chiu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23:7811-7819.
17. Hillner BE, Smith TJ. Do the large benefits justify the large costs of adjuvant breast cancer trastuzumab? J Clin Oncol 2007;25:611-613.
18. Gentleman RC, Carey VJ, Bates DM, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004;5:R80.
19. Du P, Kibbe WA, Lin SM. Lumi. A pipeline for processing Illumina microarray. Bioinformatics 2008;24: 1547-1548.
20. Smyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004; 3:R3.
21. Eisen MB, Spellman PT, Brown PO, et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998;95:14863-14868.
22. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005;102:15545-15550.
23. Tavassoli FA, Schnitt SJ. Pathology of the Breast. Elsevier: New York, 1992.
24. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;17: 747-752.
25. T Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-10874.
26. Van de Vijver MJ, He YD, vant Veer LJ, et al. A geneexpression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
27. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-2826.
28. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007;357: 39-51.
29. Weiner LM, Adams GP. New approaches to antibody therapy. Oncogene 2000;19:6144-6151.
30. Moniaux N, Andrianifahanana M, Brand RE, et al. Multiple roles of mucins in pancreatic cancer, a lethal and challenging malignancy. Br J Cancer 2004;91: 1633-1638.
31. Carraway KL, Perez A, Idris N, et al. Muc4/sialomucin complex in the mammary gland and breast cancer. J Mammary Gland Biol Neoplasia 2001;6:323-337.
32. Khoury T, Mojica W, Hicks DG, et al. Trastuzumab binding site mutations in HER2 positive invasive breast cancer: a potential predictor of less aggressive disease and trastuzumab resistance. Breast Cancer Res Treat 2006;100(Suppl 1):S31 (abstract 308).
33. Nahta R, Takahashi T, Ueno NT, et al. P27Kip1 downregulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res 2004;64:3981-3986. (Pubitemid 38697313)
34. Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004;6:117-127.
35. Lu CH, Wyszomierski SL, Tseng LM, et al. Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res 2007;13:5883-5888.
36. Nahta R, Yuan LXH, Zhang B, et al. Insulin-like growth factor-I receptor/ human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 2005;65:11118-11128.
37. Chung Y-L, Sheu M-L, Yang S-C, et al. Resistance to tamoxifen-induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer. Int J Cancer 2002;97:306-312.
38. du Manoir JM, Francia G, Man S, Mossoba M, et al. Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts. Clin Cancer Res 2006;12:904-916.
39. Sieuwerts AM, Usher PA, Meijer-van Gelder ME, et al. Concentrations of TIMP1 mRNA splice variants and TIMP-1 protein are differentially associated with prognosis in primary breast cancer. Clin Chem 2007;53: 1280-1288.